Application of hexokinase inhibitor to preparation of medicine for preventing and/or treating Alzheimer disease

A technology of Alzheimer's disease and hexokinase, which is applied in the field of preparation of drugs for the prevention and/or treatment of Alzheimer's disease and hexokinase inhibitors, and can solve problems such as the lack of content of lonidamine

Active Publication Date: 2020-07-03
XIAMEN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It can be used in the treatment of various tumors such as breast cancer, prostate cancer, lung c

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hexokinase inhibitor to preparation of medicine for preventing and/or treating Alzheimer disease
  • Application of hexokinase inhibitor to preparation of medicine for preventing and/or treating Alzheimer disease
  • Application of hexokinase inhibitor to preparation of medicine for preventing and/or treating Alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Embodiment 1: 3-BP improves the cognitive ability of Alzheimer's disease model mice

[0047] (1) Background and grouping of experimental mice

[0048] 5×FAD transgenic mice are classic AD transgenic mice, 5×FAD transgenic mice overexpress mutations in two humanized and familial Alzheimer’s disease-associated genes APP and PS1, the expression of these two genes is controlled by Initiated by the mouse prion protein promoter. The PS1-dE9 mutation of the human presenilin gene is caused by the deletion of the ninth exon of the gene, which can lead to early-onset Alzheimer's disease. Control mice were derived from littermates of wild-type mice. Nine-month-old 5×FAD mice and control mice were used in the experiment.

[0049] The experimental groups were divided into four groups: wild type mice were given control reagent group (WT), 5×FAD mice were given control reagent group (5xFAD), wild mice were given 3-BP group (WT+3-BP), 5×FAD mice were given 3-BP group (WT+3-BP), 5× ...

Embodiment 2

[0054] Example 2: Immunohistochemistry and immunofluorescence staining to detect the scavenging effect of 3-BP on Aβ in the brain of Alzheimer's disease model mice

[0055] (1) Stereotaxic intracerebroventricular injection of mouse brain

[0056] 5×FAD mice were intraperitoneally injected with 5% chloral hydrate (0.1mL / 15g). After complete anesthesia, the head hair was shaved and fixed on a brain stereotaxic instrument. Disinfect with povidone iodine, cut the scalp, find the bregma and bregma under the microscope for leveling and positioning, drill a small hole (x±1.0mm, y-0.4mm) at the ventricle with a 0.5mm drill bit, and remove bone debris , slowly insert the microsyringe into the lateral ventricle, descend to the appropriate depth coordinate (z2.2mm) and inject (3-BP, 2.5μL, 0.5mg / kg). After the injection, stop the needle for ten minutes, withdraw the needle slowly, and suture the skin of the mouse head.

[0057] (2) Tissue fixed section

[0058] After one week of intra...

Embodiment 3

[0062] Example 3: Observation of the Effect of 3-BP on the Aβ Aggregation State in Vitro by Electron Microscopy

[0063] Prepare Aβ1-42 as follows: Dilute the polypeptide dissolved in DMSO (5 mM) to 100 μM with phenol-free cold F-12 cell culture medium (Gibco), sonicate for 10 min to make freshly used oligomeric Aβ1-42 . Some peptides were cultured at 22°C and 220rpm for 72 hours to age them in vitro, and different concentrations of 3-BP were added during this process. Afterwards, culture at 4°C for 24 hours, and centrifuge at 16,000×g for 15 minutes. The collected supernatant contains Aβ1-42 aggregates, which are observed and analyzed by transmission electron microscope. Depend on image 3 It can be seen that when 3-BP is added, the aggregation state of Aβ becomes loose and the volume of multimer becomes smaller with the increase of the concentration of 3-BP added. This experiment shows that 3-BP can reduce Aβ aggregation and form smaller aggregates, which facilitates the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention discloses an application of a hexokinase inhibitor to preparation of a medicine for preventing and treating the Alzheimer disease. It is proposed that the hexokinase inhibitor, especially lonidamine and 3-bromopyruvic acid can improve the cognitive level of an Alzheimer disease model mouse, remove A beta and reduce A beta aggregation, the hexokinase inhibitor has the obviousanti-Alzheimer disease progression effect, and a basis is provided for the hexokinase inhibitor, especially the lonidamine and the 3-bromopyruvic acid to preparation of the medicine for preventing andor treating the Alzheimer disease.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to the use of hexokinase inhibitors in the preparation of medicines for preventing and / or treating Alzheimer's disease. Background technique [0002] Alzheimer's disease (Alzheimer disease, AD) is a progressive neurodegenerative disease, mainly occurs in the elderly, is an age-related, progressive memory and cognitive dysfunction as the main clinical A characteristic degenerative disease of the central nervous system, the main clinical symptoms include memory impairment, aphasia, agnosia, and executive dysfunction. The lesions of Alzheimer's disease are concentrated in the hippocampus and cerebral cortex, and the cerebral hemispheres have diffuse atrophy of the cortex, with lighter weight, narrower brain gyri, and wider brain grooves. Lesions often appear in the brain of AD patients in the early stage and accompanied by clinical symptoms. The lesion area deteriorates with age, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/416A61K31/19A61P25/28
CPCA61K31/19A61K31/416A61P25/28
Inventor 张杰冷历歌薛锦袁子淇苏晓王晗陈贞磊
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap